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Abstract
Background: Lectins are sugar-binding proteins that specifically recognize sugar complexes. Based on the specificity of
protein–sugar interactions, different lectins could be used as carrier molecules to target drugs specifically to different cells
which express different glycan arrays. In spite of lectin’s interesting biological potential for drug targeting and delivery, a
potential disadvantage of natural lectins may be large size molecules that results in immunogenicity and toxicity. Smaller
peptides which can mimic the function of lectins are promising candidates for drug targeting.
Principal Findings: Small peptide with lectin-like behavior was screened from amphibian skin secretions and its structure
and function were studied by NMR, NMR-titration, SPR and mutant analysis. A lectin-like peptide named odorranalectin was
identified from skin secretions of Odorrana grahami. It was composed of 17 aa with a sequence of YASPKCFRYPNGVLACT. L-
fucose could specifically inhibit the haemagglutination induced by odorranalectin.
125I-odorranalectin was stable in mice
plasma. In experimental mouse models, odorranalectin was proved to mainly conjugate to liver, spleen and lung after i.v.
administration. Odorranalectin showed extremely low toxicity and immunogenicity in mice. The small size and single
disulfide bridge of odorranalectin make it easy to manipulate for developing as a drug targeting system. The cyclic peptide
of odorranalectin disclosed by solution NMR study adopts a b-turn conformation stabilized by one intramolecular disulfide
bond between Cys6-Cys16 and three hydrogen bonds between Phe7-Ala15, Tyr9-Val13, Tyr9-Gly12. Residues K5, C6, F7, C16
and T17 consist of the binding site of L-fucose on odorranalectin determined by NMR titration and mutant analysis. The
structure of odorranalectin in bound form is more stable than in free form.
Conclusion: These findings identify the smallest lectin so far, and show the application potential of odorranalectin for drug
delivery and targeting. It also disclosed a new strategy of amphibian anti-infection.
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Introduction
The biological barriers between the site of drug action and drug
delivery are becoming increasingly important for the development
of effective and safe medicines as mentioned by Lehr et al and Bies
et al [1,2]. Being proteins or glycoproteins themselves, lectins bind
to sugar-moieties of the cell membrane. Typically involving a high
number of binding sites and determined by a specific sugar code,
lectin binding is usually rapid and strong. Lectins have been
focused upon for more than 20 years and are becoming excellent
candidates for drug delivery and targeting [3,4]. Some of problems
are associated with lectins because of their large molecular weights.
Molecular weights of most lectins are more than 10 KDa that likely
results in toxicity and immunogenicty [2,5]. These problems are
probably overcome by small size lectins with high target specificity.
As far as we know, two small size lectins have been found. They are
Selenocosmia huwena lectin-I [6] and h-defensin [7]. Selenocosmia
huwena lectin-I is identified from the venom of the Chinese bird
spider Selenocosmia huwena. It is composed of 32 residues including
three disulfide bridges with homology with N-terminal fragment of
great nettle lectin. h-defensin is purified from the leukocytes and
bone marrow of the rhesus macaque (Macaca mulatta). h-defensin is
an antimicrobial peptide with capability to protect cells from in vitro
infection by HIV-1. h-defensin is circular, tetracyclic peptides with
three disulfide bridges connecting its antiparallel b-sheets and
composed of 18 residues. It can specially bind to galactosylcer-
amide [7]. Although they have a small size, it is not easy to
manipulate and develop Selenocosmia huwena lectin-I and h-defensin
as drug targeting systems because of their complex circular
structures and multiple disulfide bridges.
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The smallest lectin was identified from skin secretions of
the frog, O. grahami
We purified and characterized a small peptide named
odorranalectin with lectin-like activity from skin secretions of the
frog, O. grahami (Fig. S1). It was composed of 17 amino acid
residues with a sequence of YASPKCFRYPNGVLACT contain-
ing a single disulfide bridge (Fig. 1). L-fucose could specifically
inhibit the haemagglutination induced by odorranalectin. Odor-
ranalectin is the smallest known lectin. Several cDNA clones
encoding precursors of odorranalectin were cloned from a skin
cDNA library of O. grahami. It was found to have an open reading
frame that encodes a polypeptide composed of 61 amino acids,
including the mature odorranalectin sequence (Fig. 1A, GenBank
accession EU072454). The structural organization of the precursor
is quite similar to amphibian antimicrobial peptide precursors,
comprising a signal peptide sequence, an N-terminal spacer
peptide region containing several aspartic and glutamic acid
residues, and the mature peptide at the C-terminus of the
precursor. There is a di-basic cutting site (-K
42R
43-) for trypsin-like
proteases between spacer peptide and mature peptide. The amino
acid sequences deduced from the cDNA sequences match well
with the amino acid sequences determined by Edman degradation.
Since the precursor of odorranalectin shares a similar signal and
propiece peptide with the previously identified amphibian
antimicrobial peptides [8,9] (Fig. 1B), we suspected that it had
antimicrobial activities. In contrast to our speculation, odorrana-
lectin had no antimicrobial activities (data not shown).
Microbe-agglutinating and hemagglutinating activity of
odorranalectin
Odorranalectin could strongly agglutinate intact, trypsin-, or
formaldehyde-treated rabbit erythrocytes (Fig. 2B; Table S1),
however more odorranalectin was needed for agglutinating
proteinase-treated rabbit erythrocytes. The minimum concentra-
tion (MIC) to agglutinate intact human erythrocytes is 0.75 mg/ml
(Table S1). EDTA treatment and metal cation addition to
odorranalectin did not affect the agglutinating activity, which
suggested that odorranalectin did not depend on metal cation to
exert its lectin-like activity. Considering the similarity of the overall
structure of odorranalectin precursor with amphibian antimicro-
bial peptides, some biological activities including microbe-killing,
microbe-agglutinating, and histamine-releasing, which are related
to innate immunity have been tested. Although odorranalectin had
no direct microbe-killing ability, it could agglutinate microorgan-
isms and induce histamine release from mast cells (Fig. 2C–2H;
Table S2). Among the tested microorganisms, the minimal
concentration of odorranalectin to agglutinate Escherichia coli
DH5a (Fig. 2D), Candida albicans (ATCC2002) (Fig. 2F), and
Staphylococcus aureus (ATCC2592) (Fig. 2H) is 0.625, 1.25, and
2.50 mg/ml, respectively (Table S2). E. coli DH5a was most
sensitive to odorranalectin. Furthermore, odorranalectin had
moderate histamine-releasing ability, 25 and 50 mg/ml odorrana-
lectin could induce 5.72% and 12.48% histamine release,
respectively (Table S3). Some lectins such as mannose-binding
lectin (MBL) [10–12] distributed in serum can recognize invading
microbes by binding to surface mannose residues or to
peptidoglycan. This binding triggers the lectin-activated comple-
Figure 1. cDNA sequence of odorranalectin, (A) cDNA nucleotide sequence and deduced amino acid sequence of odorranalectin
precursor. The amino sequence of mature odorranalectin is boxed. The stop codon is indicated by a star (*); (B) The precursor of odorranalectin
(LEC) shares a similar signal peptide with the antimicrobial peptide Nigrocin-OG20 (AMP) isolated from O. grahami [11]. Both of the mature peptides
are preceded by a Lys-Arg motif, which is a typical processing site for endoproteolytic cleavage. The signal peptide is given in italics. The mature
peptide is boxed. Conserved amino acid residues are shaded.
doi:10.1371/journal.pone.0002381.g001
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proteases MASP1 and via interactions with the MBL collagenous
domain. Odorranalectin has no collagenous domain. Our
experiments also demonstrated that odorrananlectin had no effect
on the lectin-activated complement pathway (data not shown).
Synergy between antimicrobial peptides has been reported
[9,13,14]. We conducted a study to explore the synergy between
the amphibian lectin and amphibian antimicrobial peptides
Nigrocin-OG13, Nigrocin-OG21 from O. grahami skin. Unexpect-
edly, while individually these peptides had no effect on HIV, in
combination they did, although with low selectivity (unpublished
data). All the results suggested that odorranalectin could exert
Figure 2. Hemagglutinating and microbe-agglutinating activities of odorranalectin. odorranalectin could agglutinate rabbit erythrocytes.
In control (A) wells no lectins were added; in sample (B) wells 4 hemagglutination doses of odorranalectin were added; 4 hemagglutination doses of
odorranalectin could also agglutinate microorganisms as illustrated in (C), untreated E.coli DH5a; (D), odorranalectin treated E.coli DH5a; (E),
untreated C. albicans; (F), odorranalectin treated C. albicans; (G), untreated S. aureus; (H), odorranalectin treated S. aureus.
doi:10.1371/journal.pone.0002381.g002
The Smallest Peptide Lectin
PLoS ONE | www.plosone.org 3 June 2008 | Volume 3 | Issue 6 | e2381some functions related to innate immunity and probably take part
in anti-infection defence of amphibian.
Carbohydrate-binding specificity of odorranalectin
Carbohydrate-binding specificity of odorranalectin was examined
by hemagglutination-inhibition test. Among the 33 tested mono-
meric sugars, only L-fucose could inhibit its hemagglutinating and
microbe-agglutinating activities (Fig. 3;TableS2). It issuggested that
L-fucose could be the ligand of odorranalectin. Surface plasmon
resonance (SPR) analysis further demonstrated that L-fucose could
specifically bind to odorranalectin with a binding affinity (KD)o f
5.47610
25 M (Fig. 3D; Table S4). The mucin-binding specificity of
odorranalectin was also investigated by SPR analyses (Fig. 3A–3C;
Table S4). Odorranalectin was immobilized on the sensor chip CM-
5 by amine coupling and four glycoproteins: Bovine submaxillary
mucin (BSM), porcine stomach mucin (PSM), fetuin, and transferrin
were used as analytes. All the glycoproteins except transferrin could
inhibit the hemagglutinating activity of odorranalectin, among
which, fetuin was the most effective inhibitor. The sensorgrams and
the kinetic data of the binding are shown in Fig. 3 and Table S4,
respectively. Transferrin did not bind to the immobilized odorra-
nalectin. The binding of all the other glycoproteins and L-fucose to
the immobilized lectin fitted best to a 1:1 binding model among the
various models in the evaluating software. Among the tested
glycoproteins, the affinity of fetuin was the strongest
(KD=2.11 610
27 M) among the analytes and that of BSM was the
weakest (KD=2.9 610
26 M). Odorranalectin binding to monomeric
sugar and glycoproteins did not require calcium. Taken together,
these results suggested that odorranalectin is a pattern-recognition
peptide that recognizes the microbe-associated molecular pattern
Figure 3. Sensor-grams showing the interaction between immobilized odorranalectin and glycoproteins or sugar with different
concentrations as indicated. (A), fetuin; (B), bovine submaxillary mucin (BSM); (C), porcine stomach mucin (PSM); (D), L-fucose; RU, resonance
units; MIC is the minimum inhibitory concentrations required for inhibition of four hemagglutination doses of odorranalectin. sucrose, D(+)-
cellobiose, D(+)-melezitose monohydrate, inulin, D(+)-raffinose pentahydrate, D(+)-galacturonic acid, lactose, D-glucose,D-ribose, D-trehalose,
isopropy-b-D-thiogalactoside, 2-nitrophenyl-b-D-galactopyranoside, dulcitol, L-sorbose,D-sorbose, D-froctose, L(+)-rhamnose monohydrate, D(+)-
xylose, D(+)-galactose, D(+)-arabinose, N-acetylgalactosamine, N-acetylglucosamine N-acetylneuraminic acid, D-sorbitol, inositol, adonitol, D-
mannose, N-acetyl-D-mannosamine, 5-bromo-4-chloro-3-indoxyl-b-D-galactopyranoside, N-glycolylneuraminc acid, D(+)-maltose monohydrate, and
heparin did not inhibit at all at concentrations up to 200 mM. Association and dissociation rate constants (ka and kd) were calculated by using BIA
evaluation 4.0 software (Biacore AB, Sweden). The affinity constant (KD) was calculated from the ka and kd. For the calculation of rate constants,
samples were appropriately diluted in 10 mM HEPES-buffered saline containing 3 mM EDTA and 0.005% surfactant P-20, pH 7.4 (HBS-EP) at various
concentrations.
doi:10.1371/journal.pone.0002381.g003
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interaction between odorranalectin and L-fucose was further
demonstrated in the NMR titration experiments.
NMR titration
To understand the structure-function relation of odorranalectin,
we studied the interaction between odorranalectin and L-fucose
using NMR titration experiments.
1H-
15N HSQC spectra were
used to monitor peak changes during the L-fucose titration process
and to map the binding site of L-fucose on odorranalectin.
Superposition of the
1H-
15N HSQC spectra of odorranalectin free
and in the complex with L-fucose was shown in Fig. 4 A. It was
observed that each of five isolated peaks related to residues K5,
C6, F7, C16 and T17, respectively, was spilt into two peaks upon
titration with L-fucose, shown in Fig. 4B, while other peaks did not
experience significant changes. This observation indicated that
odorranalectin was bound to L-fucose. Residues K5, C6, F7, C16
and T17 consist of the binding site of L-fucose on odorranalectin,
displayed in Fig. 4C. It was further confirmed by mutational
analyses. Most of mutated peptides lost the ability to bind with L-
fucose as shown in table S5. Furthermore, most peaks became
more or less stronger upon titration with L-fucose, which may
indicate that the structure of odorranalectin in bound form is more
stable than in free form. It was suggest that the L-fucose binding
may increase the rigidity of odorranalectin.
Stability of
125I-odorranalectin in vitro and mouse tissue
distribution of
125I-odorranalectin in vivo
125I is often used to label protein or polypeptide because it can
substitute a hydrogen atom in the tyrosine and has suitable
radioactive half-life (about 60 days). In this study, odorranalectin
was labeled by
125I and purified to 99% by HPLC. Purified
125I-
odorranalectin was used to study stability in plasma and tissue
distribution of mice in vivo. Fig. 5I indicated that
125I-odorrana-
lectin could exist stably in the mice plasma for at least 5 hours, and
the key point of in vitro test witnessed that
125I isotope tracer
method was suitable for further tagging investigation in vivo.
Different lectins have different carbohydrate specificities [15], and
distribution of various carbohydrates in mucous membranes is also
different. But through different routes of administration, such as
per oral, intravenous, and per nasal administration routes of
125I-
odorranalectin at an equal radiation dose, the specificity of its
glycosyl-binding may be identified. Radiocounting-time curves of
125I-odorranalectin in different tissues were plotted (Fig. 5A–5H),
Figure 4. Titration of L-fucose to odorranalectin. (A) Superposition of the
1H-
15N HSQC spectra of odorranalectin free and in the complex with
L-fucose. The molar ratios of odorranalectin to L-fucose were 1:0 (red), 1:0.25 (orange), 1:0.5 (blue), 1:0.75 (purple), 1:2 (pink), 1:3 (cyan), respectively.
(B) Each of five isolated peaks was split into two peaks upon titration with L-fucose which was indicative of interaction between odorranalectin and L-
fucose. (C) Five residues consist of the L-fucose binding site on odorranalectin, which were displayed with side-chains in the structure of
odorranalectin. Atoms C, O, N, H, S were shown in black, red, blue, light gray and yellow, respectively.
doi:10.1371/journal.pone.0002381.g004
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were shown in Table S6 and Table S7. The AUC values of liver,
spleen and lung were much larger than other tissues after
intravenous administration; this striking difference might be
caused by two reasons: 1),
125I-odorranalectin could be specifically
conjugated to liver, spleen and lung; 2), the aggregates of
125I-
odorranalectin with erythrocyte were phagocytosed by phagocytic
cells abundant in liver and spleen, and the firs-pass effect of lung.
Compared to intravenous administration, however, the amounts
of
125I-odorranalectin absorbed into blood circulation after oral
and nasal administration, seemed to no distinctions, and the
amounts through intranasal administration were even more than
that of intravenous, while the uptakes of liver, spleen and lung
were striking much less than those of intravenous injection, the
possible reason was that the radioactivity determined in the blood
after per oral or intranasal administration was not caused by
125I-
odorranalectin. According to the AUCstomach values, it was not
difficult to understand that the bulk of
125I-odorranalectin was
swallowed when per nasal administration. On the basis of the
results above,
125I-odorranalectin might be degraded or lost its
activity when absorbing through gastrointestinal tract after per
oral and nasal administration.
Immunogenicity and toxicity of odorranalectin
To assess the immunogenicity of odorranalectin, groups of mice
(n=10, seven-week-old, female) were immunized by odorrana-
lectin and other control proteins (ovalbumin, OVA, a poorly
immunogenic protein; wheat germ agglutinin, WGA), using 0.1 M
sodium bicarbonate as blank control. On days 1, 14, and 35,
100 mg OVA or odorranalectin in sterile 0.1 M sodium bicar-
bonate was intravenously administered. After three immunizations
with OVA, WGA, odorranalectin, and 0.1 M sodium bicarbonate,
the detection of specific antibodies in sera was performed by
enzyme-linked immunosorbent assay (ELISA). The maximum
specific IgG titre for OVA, WGA, and odorranalectin was 1:200,
1:1600, and 1:200, respectively, and the maximum specific IgA
titre for OVA, WGA, and odorranalectin was 1:300, 1:2000, and
1:200, respectively. Odorranalectin had similar immunogenicity
with OVA, which is a kind of poorly immunogenic protein.
Compared with another lectin (WGA), odorranalectin had
extremely low immunogenicity. Single dose acute toxicity studies
(24 h) in animals are necessary for pharmaceuticals intended for
humans. Odorranalectin was tested for acute toxicity by i.v.
delivery in female outbred mice. The maximum tolerable dose of
odorranalectin by i.v. delivery was between 75 and 100 mg/kg. It
Figure 5. Radiocounting-time curves of blood and different tissues after per oral (Rhombus), intravenous (Rectangular) and
intranasal (Triangle) administration into mice (n=3), and the stability of
125I-odorranalectin in plasma.
doi:10.1371/journal.pone.0002381.g005
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complement activation. All the results suggested that odorrana-
lectin had extremely low toxicity.
Solution structure of odorranalectin
Proton nuclear magnetic resonance (NMR) spectroscopy was
used to determine the three-dimensional structure of odorrana-
lectin in the NMR buffer described in the section of Materials and
Methods (Fig. 6, SMSDep ID code: 20001; BMRB ID code:
15556).
1H resonance assignments were performed using TOCSY
and NOESY spectra for identification of the scalar coupled spin
systems and the sequential connectivity. Totally, 187
1H-
1H
distance constraints were obtained, including 101 intraresidue
constraints, 45 sequential constraints and 29 medium constraints,
12 long range constraints. NOE distance constraints were shown
in Tables S8, while J-coupling constraints were shown in Tables
S9 which was obtained from TOCSY spectrum.
1H chemical
shifts of odorranalectin were listed in Table S10. The structure
statistics for the 20 lowest-energy structures of 200 calculated
structures was shown in Table S11. The average RMSD (root-
mean-square deviation) values for the backbone atoms and for all
heavy atoms of residues 4–16 are 0.55 A ˚ and 0.93 A ˚, respectively,
calculated by the program MOLMOL [16]. The Xxx-Pro peptide
bonds with Pro4 and with Pro10 both are in the trans-
conformation, as evidenced by the observation of dad NOEs.
Ramachandran plot analysis using the program PROCHECK
[17] showed that 60% residues were located in the most favored
region, while 35.4% residues were located in the additional
allowed regions. No residue was located in the disallowed region.
The cyclic peptide of odorranalectin adopts a b-turn confor-
mation which is stabilized by one intramolecular disulfide bond
between Cys6-Cys16 and three hydrogen bonds between Phe7-
Ala15, Tyr9-Val13, Tyr9-Gly12 (Fig.6B). It was revealed that
there were no secondary structural elements such as helix, strand
in the NMR-derived conformation, which was consistent with the
result from the circular dichroism (CD) experiment (Fig. S2).
Furthermore, both termini (residues Tyr1-Ser3, Tyr17) are quite
conformational flexible and were not included in the RMSD
calculation. Most regions of the electrostatic surface of odorrana-
lectin (Fig. 6C) are positively charged, except the region around
T17 (Fig. 6C) is negatively charged. The solution structure
disclosed by the NMR study provides a molecular basis for
understanding the function of odorranalectin.
Discussion
Together, odorranalectin identified from skin secretions of the
frog of O. grahami represents a new family of lectin. Odorranalectin
can thus be added to the growing list of amphibian skin bioactive
peptide prototypes. Amphibian skin secretions are a rich source of
biologically active peptides which participate in mechanisms used
by frogs and toads to defend against microbial infection and from
being eaten by predators [18,19]. Antimicrobial peptides and
lectins generally belong to families of bioactive peptides, which
through evolution have given rise to counterparts in microorgan-
isms. Odorranalectin is the smallest lectin, which is composed of
only 17 amino acid residues. The overall structure of odorrana-
lectin precursor is very similar to amphibian antimicrobial peptide
Figure 6. The solution structure of odorranalectin. (A) Superposition of the 20 lowest-energy conformers calculated with NOE-derived
1H-
1H
distance restraints and J-coupling restraints. Backbone, side-chains of residues 4–16 and side-chains of residues 1–3, 4 were shown in blue, red and
green, respectively. (B) The mean structure calculated from the 20 lowest-energy structures which highlighted three hydrogen bonds (green broken
lines) and one disulfide bonds (black solid line). (C) Electrostatic surface of odorranalectin which took the same orientation as that in the Panel A.
Positively charged region and negatively charged region were shown in blue and red, respectively. The electrostatic surface was calculated and
colored using the program MOLMOL [31].
doi:10.1371/journal.pone.0002381.g006
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antimicrobial peptides. All the results imply that amphibian
antimicrobial peptides and odorranalectin have the same ancestor
and odorranalectin takes part in antimicrobial defence as
antimicrobial peptides do. It also disclosed a new strategy of
amphibian anti-infection.
Although many scientific problems and technical developments
need to be solved, lectin-mediated oral drug delivery is more than
an interesting idea. Most lectins are large and are unlikely to be
used as drug carriers because of their immunogenicity and toxicity
[1]. Smaller peptides or even organic molecules which can mimic
the function of lectins are ideal candidates [1]. As the smallest
lectin, odorranalectin has potential for drug delivery and targeting
because of its several unique characters. Firstly, odorranalectin is
composed of only 17 amino acid residues with a molecular weight
of 1887.9 Da and has a single disulfide bridge that makes it easy to
manipulate and develop a drug targeting system. Secondly,
odorranalectin can specifically bind to monomeric sugar, L-fucose,
that makes odorranalectin have the ability to target special sites,
and odorranalectin was proved to mainly conjugate to liver, spleen
and lung after iv administration. Thirdly, it was apparently stable
for more than 5 hours in mice plasma that can improve its
bioavailability. Lastly, it is very important that odorranalectin has
extremely low toxicity and immunogenicity.
Materials and Methods
Materials and animals
All the information for materials and animals are provided in
supplementary materials. The animals used for the experiment
were treated according to the protocols evaluated and approved by
the ethical committee of Kunming Institute of Zoology.
Lectin purification, construction and screening of a cDNA
library
Lectin purification, mRNA preparation, cDNA library con-
struction and screening were performed as described previously
[9]. The details are provided in the supplementary materials
(Materials and Methods S1).
Peptide synthesis
Odorranalectin and its mutants synthesis and
125I-odorrana-
lectin preparation with iodogen methods were performed as
described previously [9,20]. The details are provided in the
supplementary materials (Materials and Methods S1; Figure S3).
Erythrocytes hemagglutination and inhibition assay
Intact, pronase-treated, trypsin-treated, and formaldehyde-
treated rabbit erythrocytes were prepared. Assays were carried
out in U-well microtiter plates (96 wells) as described previously
[21–23]. The details are provided in the supplementary materials
(Materials and Methods S1).
Microbe-agglutinating activities
The bacteria agglutination assay was performed according the
method described by Yu et al [24]. The details are provided in the
supplementary materials (Materials and Methods S1).
SPR Analysis
Real time detection of odorranalectin and its mutants binding to
glycoproteins and L-fucose was recorded by using a Biacore 3000
[21–24]. The details are provided in the supplementary materials
(Materials and Methods S1).
Histamine release activities
Histamine release activity was assayed according to the methods
described by Shore et al [25]. The details are provided in the
supplementary materials (Materials and Methods S1).
Stability of
125I-odorranalectin in vitro
In order to evaluate the stability of
125I- odorranalectin in vitro,a
degradation experiment of
125I-odorranalectin in mice plasma was
performed. The details are provided in the supplementary
materials (Materials and Methods S1).
Tissue distribution of
125I-odorranalectin in vivo
Sixty-three female KM mice (18,22 g) were grouped randomly
into three groups receiving oral, intravenous and intranasal
administration of
125I-odorranalectin at equal radiation dose
(400 mCi?kg
21), respectively. The detail procedures are provided
in the supplementary materials (Materials and Methods S1).
Immunogenicity and toxicity assay
Immunogenicity and toxicity were tested according to methods
described by Scott et al [26]. Groups of mice (n=10, seven-week-
old, female) were immunized by odorranalectin and other control
proteins (ovalbumin and wheat germ agglutinin), using 0.1 M
sodium bicarbonate as blank control. After three immunizations,
the detection of specific antibodies in sera was performed by
enzyme-linked immunosorbent assay (ELISA).
Nuclear magnetic resonance (NMR)
The NMR sample was prepared by dissolving 2.9 mg
odorranalectin in 500 ml NMR buffer including 20 mM
Na2HPO4, 100 mM NaCl, pH 6.0. All NMR experiments and
circular dichroic analysis were performed according to previous
methods [16,17,27–32]. The details were described in the
supplementary materials (Materials and Methods S1).
NMR titration Experiments
Titration of L-fucose to odorranalectin was performed as
follows. A sample of 10 mM odorranalectin in the HBS-EP buffer
(10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005%
surfactant P-20, pH 7.4, in 90% H2O/10% D2O), was titrated
with 90 mM L-fucose in the HBS-EP buffer too. Data were
collected with 64 and 1024 complex data points in t1 and t2
dimensions, respectively, and signals were averaged over 128
transients. At each titration point, 2D
1H-
15N HSQC spectrum
was recorded for bound odorranalectin at molar ratios of
odorranalectin to L-fucose of 1:0.25, 1:0.5, 1:0.75, 1:2, 1:3.
Resonance assignments were achieved using a combination of
TOCSY, NOESY and
1H-
15N HSQC spectra.
Data analysis
Each experiment was carried out in triplicate. Values are given
as means6SD. All the concentration data were plotted directly as
radiocounting-time curves of the blood and tissues, and the area
under the curve (AUC0Rt) was calculated by the trapezoidal rule.
The statistical differences between per oral or intranasal
administrations and intravenous administration were assessed
using student’s t test and P,0.05 as statistical significance.
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Figure S2 A: The CD spectrum of odorranalectin in NMR
buffer (20 mM Na2HPO4, 100 mM NaCl, pH6.0). B: The
estimated populations of secondary structure elements contained
in odorranalectin.
Found at: doi:10.1371/journal.pone.0002381.s003 (0.05 MB
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Figure S3 HPLC of 125I-Lectin X. A: UV detector; B:
radioactive detector (before purification); C: radioactive detector
(after purification)
Found at: doi:10.1371/journal.pone.0002381.s004 (0.18 MB
DOC)
Table S1 Erythrocytes agglutination profiles of odorranalectin.
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DOC)
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Table S4 Inhibition and binding kinetics of odorranalectin-
mediated erythrocytes hemagglutination by mono- and oligosac-
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Found at: doi:10.1371/journal.pone.0002381.s008 (0.03 MB
DOC)
Table S5 Abilities of odorranalectin and its mutants to bind with
L-fucose
Found at: doi:10.1371/journal.pone.0002381.s009 (0.03 MB
DOC)
Table S6 Area under radiocounting-time curves (AUC) of blood
and tissues after per oral, transvenous and per nasal administra-
tions into mice at 400 mCi.kg-1 dose (Mean6SD, n=3)
Found at: doi:10.1371/journal.pone.0002381.s010 (0.03 MB
DOC)
Table S7 Radiochemical purity (%) of 125I-odorranalectin
determined before and after purification (n=3)
Found at: doi:10.1371/journal.pone.0002381.s011 (0.03 MB
DOC)
Table S8 NOE restraints (upper limits of 1H-1H distances,
&#x00C5;) used for structure calculation of odorranalectin
Found at: doi:10.1371/journal.pone.0002381.s012 (0.32 MB
DOC)
Table S9 3J (HN-HA) scalar coupling constants (Hz) used for
structure calculation of odorranalectin as backbone dihedral angle
restraints
Found at: doi:10.1371/journal.pone.0002381.s013 (0.03 MB
DOC)
Table S10
1H chemical shifts of odorranalectin in H2Oa t
298 K
Found at: doi:10.1371/journal.pone.0002381.s014 (0.03 MB
DOC)
Table S11 Structure statistics from NMR structure analysis
Found at: doi:10.1371/journal.pone.0002381.s015 (0.04 MB
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